萬邦德(002082.SZ):孫公司違反反壟斷法 共計罰沒247.4萬元
格隆匯 11 月 12日丨萬邦德(002082.SZ)公佈,公司全資孫子公司萬邦德製藥集團浙江醫藥銷售有限公司(“浙江醫藥銷售公司”)於近日收到浙江省市場監督管理局出具的《行政處罰決定書》。
《行政處罰決定書》認定:浙江醫藥銷售公司在國內鹽酸溴己新原料藥市場具有市場支配地位,濫用市場支配地位實施了附加不合理交易條件,2015年10月至2016年12月,涉及注射用鹽酸溴己新制劑的銷售金額725,641.03元(不含税),獲利232,205.11元。上述行為違反了《中華人民共和國反壟斷法》第十七條第一款第(五)項“禁止具有市場支配地位的經營者從事下列濫用市場支配地位的行為:(五)沒有正當理由搭售商品,或者在交易時附加其他不合理的交易條件”的規定,構成濫用市場支配地位附加不合理交易條件的行為。
鑑於浙江醫藥銷售公司能積極配合調查並認真進行整改,實施違法行為持續時間短,根據《中華人民共和國反壟斷法》第四十七條和第四十九條的規定,決定對浙江醫藥銷售公司作出如下行政處罰:沒收違法所得232,205.11元,並處2019年度銷售額3%的罰款2,241,735.58元,共計罰沒款2,473,958.69元。
上述罰沒金額,佔浙江醫藥銷售公司2019年度營業收入和淨利潤的比例分別為3.31%、10.90%,佔公司2019年度備考合併報表營業收入和淨利潤的比例分別為0.01%、0.67%,預計對公司當期業績影響較小。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.